LATEST UPDATES » Vol 24, No. 09, September 2020 – 3D Technology: Additive Manufacturing Applications and Prospects       » Results of CD30 CAR-T Cell Therapy Trial Shows Promise for Hodgkin Lymphoma Patients       » Emerging Technologies and Innovations amid a Global Pandemic       » Monitoring COVID-19 Patients with AI-powered Platform       » Singapore Researchers Devise a Rapid COVID-19 Test Kit for the Detection of Neutralising Antibodies (NAbs) Against SARS-CoV-2       » Novel Ventilator Conceptualized by Singapore Clinicians Provides Efficient and Personalized Breathing Support for COVID-19 patients      
Vol 23, No. 07, July 2019   |   Issue PDF view/purchase
A microRNA study might cast new light on ALS treatment
Offers opportunities in developing therapies for this disease

A new discovery has unearthed a group of small regulatory RNAs, known as the mir-17~92 cluster, that protects motor neurons, a cell type that is particularly sensitive to amyotrophic lateral sclerosis (ALS).

This discovery could provide new opportunities for designing therapies for this disease. The study “Mir-17~92 Confers Differential Vulnerability of Motor Neuron Subtypes to ALS-associated Degeneration” is published in Cell Stem Cell.

ALS is a neurodegenerative disorder that progresses rapidly. The disease attacks the motor neurons controlling voluntary muscle movement. Intriguingly, not all motor neurons degenerate to the same degree. Approximately 70 per cent of ALS patients experience fast degeneration of the motor neurons controlling their leg and arm muscles. These patients lose the ability to stand and walk, and to complete everyday tasks. Ultimately, patients die from breathing difficulties due to degeneration of the motor neurons controlling the diaphragm. Unfortunately, there is no effective cure for this devastating disease.

The research team led by Dr. Jun-An Chen PhD at the Institute of Molecular Biology, Academia Sinica (Taiwan), focuses on a short form of RNA, namely microRNAs (miRNAs). The team has previously found that the mir-17~92 cluster, a group of six miRNAs, is more abundant in the limb-controlling motor neurons of developing embryos. These miRNAs cooperate to prevent the accumulation of PTEN proteins in the nucleus, thereby protecting neurons from cell death and ensuring that sufficient limb-controlling motor neurons develop during embryogenesis.

In this new study, the team revealed a critical role for mir-17~92 in adults, and unveiled its role in regulating motor neuron degeneration during ALS disease. The authors used several cell and mouse models, including a classical ALS SOD1G93A mouse model, embryonic stem cell-derived motor neurons from SOD1G93A mice, as well as human ALS SOD1L144F motor neurons derived from induced pluripotent stem cells.

Results from all these models consistently show that reduced mir-17~92 levels, together with accumulation of detrimental nuclear PTEN protein, occur prior to the death of ALS limb-controlling motor neurons. The team was able to restore mir-17~92 levels in human and mouse ALS motor neurons by a genetic approach or via virus-mediated gene therapy.

Excitingly, abnormal nuclear PTEN levels were reversed and motor neuron numbers recovered to normal levels using these approaches. Furthermore, motor deficits and lifespans of adult SOD1G93A mice were remarkably improved after single treatment with virus-delivered mir-17~92.

In addition to studying ALS linked to SOD1 mutation, Dr. Chen’s laboratory is continuing to test the rescue effects of mir-17~92 in motor neurons associated with other genetic or non-genetic causing types of human ALS disease. Dr. Chen noted “Given that global miRNA dysregulation has been observed in motor neurons from different types of ALS patients, we are optimistic that mir-17~92 gene therapy can also be applied to diverse ALS types.”

The study is funded by Academia Sinica, National Health Research Institutes and the Ministry of Science and Technology in Taiwan.

news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season
news PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products
news Singapore Biomedical Company Appointed as a Certified Service Provider by 10x Genomics
news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy